Learn about CVE-2022-29513, a cross-site scripting vulnerability in Cybozu Garoon 4.10.0 to 5.5.1. Find out its impact, affected systems, and mitigation steps.
A detailed overview of a cross-site scripting vulnerability in Cybozu Garoon version 4.10.0 to 5.5.1 that allows remote attackers to execute arbitrary scripts.
Understanding CVE-2022-29513
This section provides insights into the nature and impact of the CVE-2022-29513 vulnerability.
What is CVE-2022-29513?
The CVE-2022-29513 is a cross-site scripting vulnerability found in the Scheduler component of Cybozu Garoon versions 4.10.0 to 5.5.1. It enables a remote authenticated attacker with administrative privileges to execute arbitrary scripts on the target system.
The Impact of CVE-2022-29513
This vulnerability poses a significant risk as it allows remote attackers to manipulate the affected system by executing malicious scripts, potentially leading to the compromise of sensitive information or unauthorized system access.
Technical Details of CVE-2022-29513
In this section, we delve into the specifics of the CVE-2022-29513 vulnerability.
Vulnerability Description
The vulnerability in Scheduler of Cybozu Garoon versions 4.10.0 to 5.5.1 enables a remote authenticated attacker to perform cross-site scripting attacks, thereby executing arbitrary scripts.
Affected Systems and Versions
Cybozu Garoon versions 4.10.0 to 5.5.1 are confirmed to be affected by this cross-site scripting vulnerability.
Exploitation Mechanism
An attacker with administrative privileges can exploit this vulnerability through the Scheduler feature of Cybozu Garoon, allowing them to execute malicious scripts remotely.
Mitigation and Prevention
This section outlines the necessary steps to mitigate and prevent the exploitation of CVE-2022-29513.
Immediate Steps to Take
Long-Term Security Practices
Patching and Updates
Cybozu, Inc. has provided patches to address the CVE-2022-29513 vulnerability in versions 4.10.0 to 5.5.1. Users are advised to apply these patches immediately to secure their systems.